Literature DB >> 9696034

DOC-2/hDab2, a candidate tumor suppressor gene involved in the development of gestational trophoblastic diseases.

V Fulop1, C V Colitti, D Genest, R S Berkowitz, G K Yiu, S W Ng, J Szepesi, S C Mok.   

Abstract

Gestational trophoblastic diseases comprise a spectrum of interrelated diseases including partial mole, complete mole and gestational choriocarcinoma. Using reverse transcriptase PCR (RT-PCR) analysis, we identified higher levels of DOC-2/hDab2 expression in the normal trophoblast cells in culture than in choriocarcinoma cell lines. Subsequent study using immunohistochemistry showed high levels of DOC-2/hDab2 protein expression in normal trophoblast tissues but significantly lower levels of expression in gestational trophoblastic disease tissues, particularly in complete mole and choriocarcinoma. When DOC-2/hDab2 was transfected into the choriocarcinoma cell lines, Jar, JEG and BeWo, the stable transfectants showed significantly reduced growth rate in culture. These data suggest that down regulation of DOC-2/hDab2 may play an important role in the development of gestational trophoblastic diseases.

Entities:  

Mesh:

Substances:

Year:  1998        PMID: 9696034     DOI: 10.1038/sj.onc.1201955

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  23 in total

1.  Power of the eternal youth: Nanog expression in the gestational choriocarcinoma.

Authors:  Ie-Ming Shih; Kuan-Ting Kuo
Journal:  Am J Pathol       Date:  2008-08-28       Impact factor: 4.307

2.  Disabled-2 heterozygous mice are predisposed to endometrial and ovarian tumorigenesis and exhibit sex-biased embryonic lethality in a p53-null background.

Authors:  Dong-Hua Yang; Zia Fazili; Elizabeth R Smith; Kathy Qi Cai; Andres Klein-Szanto; Cynthia Cohen; Ira R Horowitz; Xiang-Xi Xu
Journal:  Am J Pathol       Date:  2006-07       Impact factor: 4.307

3.  Disabled-2 is transcriptionally regulated by ICSBP and augments macrophage spreading and adhesion.

Authors:  Frank Rosenbauer; Axel Kallies; Marina Scheller; Klaus-Peter Knobeloch; Charles O Rock; Maike Schwieger; Carol Stocking; Ivan Horak
Journal:  EMBO J       Date:  2002-02-01       Impact factor: 11.598

4.  Disabled-2; an autophagic and apoptotic switch.

Authors:  Yong Jiang; Alec N Woosley; Philip H Howe
Journal:  Cell Cycle       Date:  2016-08-25       Impact factor: 4.534

5.  Dab2, a negative regulator of DC immunogenicity, is an attractive molecular target for DC-based immunotherapy.

Authors:  Md Selim Ahmed; Se Eun Byeon; Yideul Jeong; Mohammad Alam Miah; Md Salahuddin; Yoon Lee; Sung-Soo Park; Yong-Soo Bae
Journal:  Oncoimmunology       Date:  2015-02-03       Impact factor: 8.110

6.  Promoter hypermethylation of multiple genes in hydatidiform mole and choriocarcinoma.

Authors:  Wei-Cheng Xue; Kelvin Y K Chan; Hui-Chen Feng; Pui-Man Chiu; Hextan Y S Ngan; Sai-Wah Tsao; Annie N Y Cheung
Journal:  J Mol Diagn       Date:  2004-11       Impact factor: 5.568

7.  Dual roles for the Dab2 adaptor protein in embryonic development and kidney transport.

Authors:  Shelli M Morris; Michelle D Tallquist; Charles O Rock; Jonathan A Cooper
Journal:  EMBO J       Date:  2002-04-02       Impact factor: 11.598

8.  Loss of disabled-2 expression is an early event in esophageal squamous tumorigenesis.

Authors:  Kumar Anupam; Chatopadhyay Tusharkant; Siddhartha Datta Gupta; Ralhan Ranju
Journal:  World J Gastroenterol       Date:  2006-10-07       Impact factor: 5.742

9.  Putative tumour-suppressor gene DAB2 is frequently down regulated by promoter hypermethylation in nasopharyngeal carcinoma.

Authors:  Joanna H Tong; David C Ng; Shuk L Chau; Ken K So; Patrick P Leung; Tin L Lee; Raymond W Lung; Michael W Chan; Anthony W Chan; Kwok W Lo; Ka F To
Journal:  BMC Cancer       Date:  2010-06-03       Impact factor: 4.430

10.  Nuclear beta-catenin and Ki-67 expression in choriocarcinoma and its pre-malignant form.

Authors:  S C C Wong; A T C Chan; J K C Chan; Y M D Lo
Journal:  J Clin Pathol       Date:  2006-02-07       Impact factor: 3.411

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.